ZILRETTA (triamcinolone acetonide extended-release injectable suspension)
Product · Pharmaceutical / drug by Viatris
Non-opioid extended-release therapy for osteoarthritis knee pain.
ZILRETTA is an extended-release injectable suspension of triamcinolone acetonide for the management of osteoarthritis knee pain. It offers a non-opioid alternative for sustained pain relief in the U.S. market.
- Languages
- English
- Indications
- Management of osteoarthritis knee pain
- Forms and strengths
- Extended-release injectable suspension
- Active Ingredient
- Triamcinolone acetonide
- Formulation
- Extended-release injectable suspension
- Primary Indication
- Osteoarthritis knee pain
- Therapeutic Class
- Non-opioid pain therapy
- Indicated for osteoarthritis knee pain management
- Non-opioid pain management therapy
- Extended-release injectable suspension formulation
- Patent-protected medicine marketed in the U.S.
Overview
ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an innovative medicine indicated for the management of osteoarthritis knee pain. It serves as a non-opioid treatment option for patients and healthcare providers seeking alternatives to traditional pain management therapies. The product utilizes extended-release technology to deliver triamcinolone acetonide, providing sustained relief for chronic knee pain. It is a patent-protected, high-margin medicine currently marketed in the United States. Viatris plans to leverage its global infrastructure and medical affairs capabilities to expand the product's reach into international markets.
Clinical Applications
- Osteoarthritis Knee Pain Management: ZILRETTA is a triamcinolone acetonide extended-release injectable suspension specifically indicated for the management of osteoarthritis knee pain.
- Non-Opioid Therapy: The product provides a non-opioid treatment option for patients and healthcare providers seeking alternatives in pain management.
- Extended-Release Technology: ZILRETTA utilizes extended-release technology to provide sustained relief for patients suffering from chronic knee pain.
Market and Availability
- U.S. Market Presence: The product is a patent-protected medicine currently marketed in the United States.
- Global Expansion Plans: Viatris intends to expand the reach of ZILRETTA across selected markets within its international infrastructure.
Use cases
- Healthcare providers administer ZILRETTA to patients suffering from osteoarthritis knee pain to provide non-opioid relief.
- Patients seeking long-term management of chronic knee pain use this extended-release injectable suspension for sustained treatment.
Specifications
- Indications
- Management of osteoarthritis knee pain
- Forms and strengths
- Extended-release injectable suspension
- Availability
- Marketed in the United States with plans for international expansion
- Active Ingredient
- Triamcinolone acetonide
- Formulation
- Extended-release injectable suspension
- Primary Indication
- Osteoarthritis knee pain
- Therapeutic Class
- Non-opioid pain therapy
Added by AntSpace from public sources (newsroom.viatris.com).